ProQR Therapeutics NV has once again successfully defended a crucial patent for its groundbreaking RNA editing platform Axiomer This achievement follows the companys victory in fending off opposition against its key patent EP B filed with the European Patent Office

Tiziana Life Sciences Ltd recently announced a significant development regarding its lead candidate foralumab in a study highlighted by Neurology Today the official news source of the American Academy

Vertex Pharmaceuticals Incorporated has unveiled significant progress in its suzetrigine pain program potentially marking a breakthrough in acute and neuropathic pain treatment Suzetrigine an oral selective

PharmaTher Holdings Ltd a specialized pharmaceutical firm has received a Complete Response Letter regarding its Priority Original Abbreviated New Drug Application

Evaxion Biotech AS a clinicalstage TechBio company specializing in AIImmunology powered vaccines has achieved a significant milestone in its EVX Phase trial for metastatic melanoma

ABVC BioPharma Inc has unveiled a significant licensing deal with OncoX a company specializing in oncology dietary supplements with the goal of advancing treatments for NonSmall Cell Lung Cancer

CorMedix Inc a biopharmaceutical company focused on developing and commercializing therapeutic products for lifethreatening diseases and conditions today announced that the Center for Medicare Medicaid Services has determined that DefenCath meets the criteria for a Transitional Drug AddOn

Hepion Pharmaceuticals Inc a clinicalstage biopharmaceutical company that has been developing a treatment for nonalcoholic steatohepatitis hepatocellular carcinoma

IMUNON Inc a clinicalstage drugdevelopment company focused on developing nonviral DNAmediated immunotherapy and nextgeneration vaccines announces receipt of clearance from the US Food and Drug Administration to begin a Phase clinical trial with a seasonal COVID booster vaccine

YS Biopharma Co Ltd a global biopharmaceutical company dedicated to discovering developing manufacturing and delivering new generations of vaccines

RevolKa Ltd a venturebacked biotech company providing a gamechanging protein engineering technology platform and La Jolla Institute for Immunology agreed to start a research collaboration to create antigens for the nextgeneration vaccines to deliver innovative solutions

Essential Pharma an international specialty pharma group focused on ensuring that patients have sustainable access to low volume clinically differentiated niche pharmaceutical products across key